Kezar Life Sciences Initiates Major Overhaul Following Regulatory Setback

Biotechnology firm Kezar Life Sciences is embarking on a fundamental strategic shift after encountering a significant regulatory obstacle. The U.S. Food and Drug Administration (FDA) declined to approve a pivotal study design for the company’s lead drug candidate, Zetomipzomib, triggering an extensive corporate review, substantial cost-cutting measures, and workforce reductions affecting 70% of employees.

The company’s third-quarter 2025 financial results reveal the immediate impact of this strategic pivot:
* Quarterly net loss reached $11.2 million ($1.53 per share)
* This represents an improvement over the $20.3 million loss recorded during the same period last year
* Cash reserves diminished to $90.2 million as of September 2025, down from $132.2 million in December 2024
* Research and development Read more...